Literature DB >> 12426269

High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension.

James W Chu1, Peter N Kao, John L Faul, Ramona L Doyle.   

Abstract

STUDY
OBJECTIVES: An association between thyroid disease and pulmonary arterial hypertension (PAH) has been reported, yet the pathogenetic relationship between these conditions remains unclear. Because immune system dysfunction may underlie this association, we sought to determine the prevalence of autoimmune thyroid disease (AITD) in patients with PAH. DESIGN AND
SETTING: Prospective observational study at a single academic institution. PATIENTS: Sixty-three consecutive adults with PAH (ie, sustained pulmonary artery systolic pressure, > 25 mm Hg) were evaluated for clinical, biochemical, and serologic features of AITD. MEASUREMENTS: Thyroid gland dysfunction was determined by clinical examination for goiter, and by biochemical measurements of thyrotropin and free thyroxine. Immune system dysfunction was determined by serologic measurements of antibodies to thyroglobulin and thyroid peroxidase. First-degree family history of AITD also was ascertained in order to investigate for genetic clustering of autoimmunity.
RESULTS: Thirty-one patients (49%; 95% confidence interval [CI], 37 to 62%) received diagnoses of AITD. Eighteen patients were newly diagnosed, and 9 patients required the initiation of pharmacologic treatment. There was no chronologic relationship between the diagnosis or treatment of PAH and that of AITD. Sixteen patients (25%; 95% CI, 15 to 36%) had 24 first-degree family members with AITD.
CONCLUSIONS: Approximately half of the patients with PAH have concomitant AITD. These two conditions may be linked by a common immunogenetic susceptibility, and the elucidation of this association may advance the understanding of the pathophysiology and treatment of PAH. Systematic surveillance for occult thyroid dysfunction in patients with PAH may prevent the hemodynamic exacerbation of right heart failure.

Entities:  

Mesh:

Year:  2002        PMID: 12426269     DOI: 10.1378/chest.122.5.1668

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  37 in total

1.  Graves' disease and pulmonary hypertension: report of 2 cases.

Authors:  Salim S Virani; Cesar E Mendoza; Alexandre C Ferreira; Eduardo de Marchena
Journal:  Tex Heart Inst J       Date:  2003

2.  Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry.

Authors:  Francisco J García-Hernández; María J Castillo-Palma; Carles Tolosa-Vilella; Alfredo Guillén-Del Castillo; Manuel Rubio-Rivas; Mayka Freire; José A Vargas-Hitos; José A Todolí-Parra; Mónica Rodríguez-Carballeira; Gerard Espinosa-Garriga; Dolores Colunga-Argüelles; Norberto Ortego-Centeno; Luis Trapiella-Martínez; María M Rodero-Roldán; Xavier Pla-Salas; Isabel Perales-Fraile; Isaac Pons-Martín Del Campo; Antonio J Chamorro; Rafael A Fernández-de la Puebla Giménez; Ana B Madroñero-Vuelta; Manuel Ruíz-Muñoz; Vicent Fonollosa-Pla; Carmen P Simeón-Aznar
Journal:  Clin Rheumatol       Date:  2018-12-07       Impact factor: 2.980

Review 3.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

4.  Pediatric pulmonary arterial hypertension and hyperthyroidism: a potentially fatal combination.

Authors:  Christine M Trapp; Robert W Elder; Adrienne T Gerken; Aviva B Sopher; Shulamit Lerner; Gaya S Aranoff; Erika B Rosenzweig
Journal:  J Clin Endocrinol Metab       Date:  2012-05-23       Impact factor: 5.958

5.  Pulmonary hypertension and Hashimoto's thyroiditis: does a relationship exist?

Authors:  Marco Matteo Ciccone; Annapaola Zito; Anna Ciampolillo; Michele Gesualdo; Pierluigi Zaza; Marica Rodio; Mariapaola Barbaro; Sergio Di Molfetta; Pietro Scicchitano
Journal:  Endocrine       Date:  2014-07-25       Impact factor: 3.633

Review 6.  Current clinical management of pulmonary arterial hypertension.

Authors:  Roham T Zamanian; Kristina T Kudelko; Yon K Sung; Vinicio de Jesus Perez; Juliana Liu; Edda Spiekerkoetter
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 7.  Pulmonary hypertension in thyroid diseases.

Authors:  Pietro Scicchitano; Ilaria Dentamaro; Francesco Tunzi; Gabriella Ricci; Santa Carbonara; Fiorella Devito; Annapaola Zito; Anna Ciampolillo; Marco Matteo Ciccone
Journal:  Endocrine       Date:  2016-03-19       Impact factor: 3.633

8.  Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.

Authors:  Aravind A Menon; Sandeep Sahay; Lewis E Braverman; Harrison W Farber
Journal:  Lung       Date:  2019-11-06       Impact factor: 2.584

Review 9.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

10.  Identification of candidate genes in scleroderma-related pulmonary arterial hypertension.

Authors:  Dmitry N Grigoryev; Stephen C Mathai; Micah R Fisher; Reda E Girgis; Ari L Zaiman; Traci Housten-Harris; Christopher Cheadle; Li Gao; Laura K Hummers; Hunter C Champion; Joe G N Garcia; Fredrick M Wigley; Rubin M Tuder; Kathleen C Barnes; Paul M Hassoun
Journal:  Transl Res       Date:  2008-02-01       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.